Category: BÜHLMANN Quantum Blue® Infliximab Assay Citations

US: BÜHLMANN Quantum Blue® Infliximab is for Research Use Only. Not for use in diagnostic procedures in the US. Canada: Health Canada License: 98838
The citation list should be used for information only.

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Bodini, G. et al. Therapeutic Drug Monitoring in Crohn's Disease Patients, A Comparison Between Homogenous Mobility Shift Assay and Point of Care Method.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain.  P1750.  Read Citation BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health
Continue Reading

The New Biosimilar of Infliximab SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® Infliximab Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of infliximab SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays.  Journal of Crohns and Colitis.  2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health Canada License:
Continue Reading

A Pilot Study Using Point of Care Testing for Infliximab and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® Infliximab Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif.  P711 A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response.  Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from this
Continue Reading

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Continue Reading